> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-244/
- Published: 2019-10-27T12:00:00.000Z
- Updated: 2026-09-15T01:59:09.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145354

[**Orthopedic Surgical Instruments Put Into Class 2**](https://www.fdaweb.com/orthopedic-surgical-instruments-put-into-class-2/)  
*Federal Register* notice: FDA classifies orthopedic surgical instrumentation designed for osteochondral implants with press-fit fixation into Class 2 (special controls). 10/25/2019  

[**Draft Guide on Homeopathic Drug Products**](https://www.fdaweb.com/draft-guide-on-homeopathic-drug-products/)  
*Federal Register* notice: FDA makes available a revised draft guidance entitled “Drug Products Labeled as Homeopathic.” 10/25/2019

[**Allergan NDA Lo Minastrin FE Withdrawn**](https://www.fdaweb.com/allergan-nda-lo-minastrin-fe-withdrawn/)  
*Federal Register* notice: FDA withdraws the NDA approval of Allergan Pharmaceuticals’ Lo Minastrin FE because it is no longer marketed. 10/25/2019  

[**Internal Therapeutic Massagers Put Into Class 2**](https://www.fdaweb.com/internal-therapeutic-massagers-put-into-class-2/)  
*Federal Register* notice: FDA classifies internal therapeutic massagers into Class 2 (special controls). 10/25/2019 

[**Five Class 2 Devices Exempt from 510(k)**](https://www.fdaweb.com/five-class-2-devices-exempt-from-510-k/)  
*Federal Register* notice: FDA announces its decision to exempt a list of Class 2 devices from premarket notification requirements. 10/25/2019

[**Draft Guide on Postmarketing Studies/Trials**](https://www.fdaweb.com/draft-guide-on-postmarketing-studies-trials/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Postmarketing Studies and Clinical Trials — Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act.” 10/24/2019  

[**Device Recognized Standards List Modified**](https://www.fdaweb.com/device-recognized-standards-list-modified-2/)  
*Federal Register* notice: FDA makes available its listing of “Modifications to the List of Recognized Standards, Recognition List Number: 052.” 10/24/2019 

[**Draft Guide on Breast Implant Labeling**](https://www.fdaweb.com/draft-guide-on-breast-implant-labeling/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Breast Implants — Certain Labeling Recommendations to Improve Patient Communication.” 10/24/2019

[**Info Collection Extension for Social and Behavioral Research**](https://www.fdaweb.com/info-collection-extension-for-social-and-behavioral-research/)  
*Federal Register* notice: FDA sends to OMB an information collection extension for “Data to Support Social and Behavioral Research as Used by the Food and Drug Administration.” 10/24/2019

[**Proamatine Not Withdrawn Due to Safety/Efficacy**](https://www.fdaweb.com/login.php?sa=v&aid=D5145291&cate=FR&stid=%241%24.h0.td%2F.%24yW0rquxxTg3E.4.wMoQ961)  
*Federal Register* notice: FDA determines that Shire’s Proamatine (midodrine hydrochloride) tablets, 2.5milligrams (mg), 5mg, and 10 mg, were not withdrawn from sale for safety or effectiveness reasons. 10/21/2019